Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.54 |
| ▸ | JAK3 | P52333 | 9/20 | 0.54 |
| ▸ | BTK | Q06187 | 6/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24927490 | 0.91 | LCK (0.59) | LCKJAK3BTKEGFRSYK | |
| SCHEMBL21946318 | 0.91 | LCK (0.59) | LCKJAK3BTKEGFRSYK | |
| SCHEMBL21855164 | 0.91 | LCK (0.59) | LCKJAK3BTKEGFRSYK | |
| SCHEMBL31039906 | 0.91 | LCK (0.59) | LCKJAK3BTKEGFRSYK | |
| SCHEMBL23484941 | 0.85 | JAK3 (0.71) | LCKJAK3BTKEGFR | |
| SCHEMBL21855190 | 0.85 | JAK3 (0.68) | LCKJAK3BTKEGFR | |
| SCHEMBL21946887 | 0.85 | JAK3 (0.64) | LCKJAK3BTKEGFR | |
| SCHEMBL23081217 | 0.85 | LCK (0.61) | LCKJAK3BTKEGFRSYK | |
| SCHEMBL24926197 | 0.84 | LCK (0.47) | LCKJAK3BTKEGFRJAK2 | |
| SCHEMBL21946363 | 0.84 | JAK3 (0.72) | LCKJAK3BTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |